[go: up one dir, main page]

MX2015014063A - Composicion anti tumoral que comprende un inhibidor selectivo pi3kbeta y un inhibidor selectivo pi3kalfa. - Google Patents

Composicion anti tumoral que comprende un inhibidor selectivo pi3kbeta y un inhibidor selectivo pi3kalfa.

Info

Publication number
MX2015014063A
MX2015014063A MX2015014063A MX2015014063A MX2015014063A MX 2015014063 A MX2015014063 A MX 2015014063A MX 2015014063 A MX2015014063 A MX 2015014063A MX 2015014063 A MX2015014063 A MX 2015014063A MX 2015014063 A MX2015014063 A MX 2015014063A
Authority
MX
Mexico
Prior art keywords
selective inhibitor
pi3kbeta
pi3kalpha
tumoral
composition
Prior art date
Application number
MX2015014063A
Other languages
English (en)
Inventor
Carlos Garcia-Echeverria
Angela Virone-Oddos
Hélène Bonnevaux
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2015014063A publication Critical patent/MX2015014063A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se refiere a una combinación de un inhibidor selectivo PI3Kß con un inhibidor selectivo Pl3Ka para su uso en el tratamiento del cáncer.
MX2015014063A 2013-04-05 2014-04-03 Composicion anti tumoral que comprende un inhibidor selectivo pi3kbeta y un inhibidor selectivo pi3kalfa. MX2015014063A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13305448 2013-04-05
PCT/EP2014/056696 WO2014161938A1 (en) 2013-04-05 2014-04-03 Anti-tumoral composition comprising a pi3kbeta-selective inhibitor and a pi3kalpha-selective inhibitor

Publications (1)

Publication Number Publication Date
MX2015014063A true MX2015014063A (es) 2015-12-11

Family

ID=48142712

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014063A MX2015014063A (es) 2013-04-05 2014-04-03 Composicion anti tumoral que comprende un inhibidor selectivo pi3kbeta y un inhibidor selectivo pi3kalfa.

Country Status (11)

Country Link
US (1) US20160030440A1 (es)
EP (1) EP2981261A1 (es)
KR (1) KR20150123931A (es)
CN (1) CN105163736A (es)
AU (1) AU2014247032A1 (es)
BR (1) BR112015025101A2 (es)
CA (1) CA2908640A1 (es)
MX (1) MX2015014063A (es)
RU (1) RU2015142258A (es)
SG (1) SG11201507720PA (es)
WO (1) WO2014161938A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025264581A1 (en) * 2024-06-17 2025-12-26 Leapfrog Bio, Inc. P110 inhibitors for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
EA021088B1 (ru) 2009-07-02 2015-04-30 Санофи Производные (6-оксо-1,6-дигидропиримидин-2-ил)амида, их получение и их фармацевтическое применение в качестве ингибиторов фосфорилирования akt (pkb)
WO2012062694A1 (en) * 2010-11-08 2012-05-18 Novartis Ag Use of 2-carboxamide cycloamino urea derivatives in the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
CA2817287A1 (en) * 2010-11-11 2012-05-18 Bayer Intellectual Property Gmbh Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines
EP2640367A2 (en) * 2010-11-15 2013-09-25 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
EP2570127A1 (en) * 2011-09-16 2013-03-20 Sanofi Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors

Also Published As

Publication number Publication date
CN105163736A (zh) 2015-12-16
US20160030440A1 (en) 2016-02-04
KR20150123931A (ko) 2015-11-04
CA2908640A1 (en) 2014-10-09
SG11201507720PA (en) 2015-10-29
BR112015025101A2 (pt) 2017-07-18
RU2015142258A (ru) 2017-05-12
WO2014161938A1 (en) 2014-10-09
EP2981261A1 (en) 2016-02-10
AU2014247032A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
IL304851A (en) Tazematostat in combination with an acceptable treatment factor for use in the treatment of cancer
IL256874B (en) Immune checkpoint suppressors for use in the treatment of blood-borne cancers
IL273090B (en) Methods and preparations for the treatment of cancer
GB2516814B (en) Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
GB2513167B (en) Tetrahydrocannabivarin for use in the treatment of nausea and vomiting
MX2015011897A (es) Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
AU356311S (en) Spa
MX2015006478A (es) Inhibidores de glutaminasa y metodos de empleo.
AU351317S (en) Toothbrush
MX377593B (es) Composiciones para usar en el tratamiento de cáncer renal.
AU350280S (en) Apparatus for skin treatment
PT2956471T (pt) Composição inibidora de il-1beta e sua utilização
HUE052930T2 (hu) DNQ vagy DNQ-87 alkalmazása PARP1-inhibitorral kombinációban rák kezelésére
IN2014DN11078A (es)
PH12016501838A1 (en) Compounds and their methods of use
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
MX2015013378A (es) Uso de sedoheptulosa para la prevencion y tratamiento de inflamacion.
PL3041459T3 (pl) Kompozycje przydatne w zapobieganiu lub leczeniu raka skóry
MX2015014063A (es) Composicion anti tumoral que comprende un inhibidor selectivo pi3kbeta y un inhibidor selectivo pi3kalfa.
AU355724S (en) Tensioner bracket
AU353403S (en) Respirator
UA91089U (uk) Застосування препарату "біоглобін-у" як препарату для корекції гіпотиреоїдних станів в експерименті
AU362428S (en) Absorbent article